Cannabis Operators Stuck in Tax Limbo as IRS Delays 280E Guidance
Cannabis businesses await IRS guidance on tax deductions following the DEA's recommendation to reschedule marijuana to Schedule III, leaving...
Closed · back Mon 8am PT
Call (650) 955-1836Today: 8am–5pm PT · Mon–Fri 8am–5pm PT
We'll call you back when we open, Mon from 8am PT.
Cannabis businesses await IRS guidance on tax deductions following the DEA's recommendation to reschedule marijuana to Schedule III, leaving...
Business
Illinois recreational cannabis retailers are adding medical licenses to access federal tax relief under Section 280E and DEA registration el...
Legislation
DEA has published the December rescheduling hearing transcript, advancing the process toward a decision on moving marijuana to Schedule III....
Legislation
State marijuana regulators say they can't advise licensed businesses on rescheduling impacts because federal agencies haven't issued guidanc...
Legislation
Congressional lawmakers are demanding the IRS provide immediate tax guidance for cannabis businesses following marijuana's rescheduling to S...
Business
DEA rescheduling would end IRS 280E tax penalties that forced cannabis companies into 70%+ effective tax rates, potentially unlocking $3B+ i...
Business
New analysis warns that Trump-era tariffs on imported cultivation equipment could offset tax savings from cannabis rescheduling, creating wi...
Business
Medical cannabis operators are rushing to register with the DEA following marijuana rescheduling, hoping to secure 280E tax relief despite u...
Legislation
Nearly 400 cannabis businesses registered with the DEA's new portal in 72 hours, racing to meet a June 26 deadline for 280E tax relief under...
Business
Trump's marijuana rescheduling to Schedule III provides tax relief only for cultivation and manufacturing operations, while most dispensarie...
Legislation
The Trump administration rescheduled cannabis to Schedule III, providing tax relief to licensed operators but stopping short of full legaliz...
Business
Cannabis companies are pursuing clinical trial partnerships and expansion strategies in anticipation of marijuana's potential rescheduling t...